Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998 Jul;55(7):937-45. PubMed.

AlzBiomarker Database

Meta-Analysis

Curated Study Data

Biomarker
(Source)		 Cohort
(N)		 Measurement
Mean ± SD		 Method;
Assay Name;
Manufacturer		 Diagnostic
Criteria
Aβ42
(CSF)		 AD
(82)		 833 ± 379
pg/mL		 ELISA;
Other/Not Specified;
In-house		 McKhann et al., 1984
Aβ42
(CSF)		 CTRL-
CNC
(60)		 1485 ± 473
pg/mL		 ELISA;
Other/Not Specified;
In-house
tau-total
(CSF)		 AD
(82)		 663 ± 481
pg/mL		 ELISA;
Other/Not Specified;
In-house		 McKhann et al., 1984
tau-total
(CSF)		 CTRL-
CNC
(60)		 387 ± 167
pg/mL		 ELISA;
Other/Not Specified;
In-house

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. Alzheimer Activism: How To Modernize Clinical Trials?

Research Timeline Event

  1. CSF Aβ, CSF Aβ/tau ratio predicts decline in cognitively normal elderly and FAD mutation carriers

AlzBiomarker

  1. AD vs CTRL : Aβ42 (CSF)
  2. CTRL vs AD : Aβ42 (CSF)
  3. AD vs CTRL : tau-total (CSF)
  4. CTRL vs AD : tau-total (CSF)